Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).

Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for an undisclosed upfront payment.

Read the full 382 word article

User Sign In